Arthrosi Therapeutics has closed a $153 million Series E funding round. This late-stage biotechnology company is focused on developing a next-generation URAT1 inhibitor, which has the potential to be ...

Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can ...

Please provide your email address to receive an email when new articles are posted on . Participants briefed on biological causes were more likely to believe that long-term medication can improve gout ...

INDIANAPOLIS (WISH) — Gout is described as the most painful arthritic condition, and yet it's nicknamed the "disease of kings." That's because it was historically understood as only caused by diet and ...